PMID- 29446832
OWN - NLM
STAT- MEDLINE
DCOM- 20190930
LR  - 20190930
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
VI  - 88
IP  - 5
DP  - 2018 May
TI  - An assessment of (18) F-FDG PET/CT for thoracic screening and risk stratification 
      of pulmonary nodules in multiple endocrine neoplasia type 1.
PG  - 683-691
LID - 10.1111/cen.13573 [doi]
AB  - CONTEXT: Bronchopulmonary neuroendocrine tumours (bpNETs) and thymic carcinoid 
      (ThC) are features of multiple endocrine neoplasia type 1 (MEN 1), and 
      surveillance guidelines recommend periodic thoracic imaging. The optimal thoracic 
      imaging modality and screening frequency remain uncertain as does the prognosis 
      of small lung nodules when identified. OBJECTIVES: To evaluate fluorodeoxyglucose 
      positron emission tomography/computed tomography ((18) F-FDG PET/CT) for 
      identification and prognostic assessment of thoracic lesions in MEN 1. DESIGN: 
      Retrospective observational study. SETTING AND PARTICIPANTS: Fifty consecutive 
      MEN 1 patients undergoing screening with (18) F-FDG PET/CT at a tertiary referral 
      hospital between July 2011 and December 2016. INTERVENTIONS: (18) F-FDG PET/CT. 
      OUTCOME MEASURES: Pulmonary and thymic lesion prevalence, size, functional 
      characteristics and behaviour. RESULTS: Thirteen patients (26.0%) exhibited 
      pulmonary nodules with multiple nodules identified in nine (18.0%). An 
      asymptomatic 31 mm FDG-avid ThC was identified in one patient (2%). Of the 13 
      patients with pulmonary nodules, four (8.0%) exhibited 13 FDG-avid nodules (mean 
      size 10.1 +/- 9.1 mm), and nine (18.0%) demonstrated 26 FDG nonavid nodules (mean 
      size 6.9 +/- 5.8 mm). All FDG-avid lesions increased in size vs 11 (42.3%) FDG 
      nonavid lesions (P = .0004). For FDG-avid and nonavid nodules, the median 
      doubling time was 24.2 months (IQR 11.4-40.7) and 48.6 months (IQR 37.0-72.2), 
      respectively. Nodule resection was undertaken in two patients, typical bronchial 
      carcinoid diagnosed in one (FDG nonavid) and metastatic renal cell carcinoma in 
      the second (FDG avid). CONCLUSION: Thoracic imaging with (18) F-FDG PET/CT 
      effectively identifies pulmonary nodules and ThC. FDG-avid pulmonary lesions are 
      significantly more likely to progress than nonavid lesions.
CI  - (c) 2018 John Wiley & Sons Ltd.
FAU - So, Alvin
AU  - So A
AUID- ORCID: 0000-0002-7587-7371
AD  - Department of Medical Imaging, Royal Hobart Hospital, Hobart, TAS, Australia.
FAU - Pointon, Owen
AU  - Pointon O
AD  - Department of Nuclear Medicine, Royal Hobart Hospital, Hobart, TAS, Australia.
FAU - Hodgson, Richard
AU  - Hodgson R
AD  - Department of Medical Imaging, Royal Hobart Hospital, Hobart, TAS, Australia.
FAU - Burgess, John
AU  - Burgess J
AD  - Department of Diabetes & Endocrinology, Royal Hobart Hospital, Hobart, TAS, 
      Australia.
AD  - School of Medicine, University of Tasmania, Hobart, TAS, Australia.
LA  - eng
PT  - Journal Article
DEP - 20180306
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - Fluorodeoxyglucose F18/*analysis
MH  - Humans
MH  - Kidney Neoplasms/diagnostic imaging
MH  - Lung Neoplasms/*diagnostic imaging
MH  - Male
MH  - Middle Aged
MH  - Multiple Endocrine Neoplasia Type 1/*diagnostic imaging
MH  - Positron Emission Tomography Computed Tomography/*methods
MH  - Retrospective Studies
OTO - NOTNLM
OT  - bronchopulmonary neuroendocrine tumour
OT  - computed tomography
OT  - fluorodeoxyglucose (18F) positron emission tomography
OT  - multiple endocrine neoplasia type 1
OT  - pulmonary nodules
OT  - thoracic screening
OT  - thymic carcinoid
EDAT- 2018/02/16 06:00
MHDA- 2019/10/01 06:00
CRDT- 2018/02/16 06:00
PHST- 2017/11/19 00:00 [received]
PHST- 2018/02/03 00:00 [revised]
PHST- 2018/02/06 00:00 [accepted]
PHST- 2018/02/16 06:00 [pubmed]
PHST- 2019/10/01 06:00 [medline]
PHST- 2018/02/16 06:00 [entrez]
AID - 10.1111/cen.13573 [doi]
PST - ppublish
SO  - Clin Endocrinol (Oxf). 2018 May;88(5):683-691. doi: 10.1111/cen.13573. Epub 2018 
      Mar 6.